{
  "abstract": "Every year, 60–80% of the 134 million babies born worldwide are likely to develop jaundice, with about 18% or 24 million diagnosed with clinically significant hyperbilirubinaemia.1 2 Severe jaundice (typically measuring total serum or plasma bilirubin (TSB) of ≥20 mg/dL or 342 µmol/L)1 is a leading cause of hospitalisation in the first week of life. It accounts for up to 35% of hospital readmissions in the first month of life.3 Severe jaundice is estimated to affect at least 481 000 term or near-term newborns annually, of whom 114 000 die, and more than 63 000 survive with moderate or severe disability.4 The vast majority (over 75%) of the affected infants reside in sub-Saharan Africa and South Asia. This viewpoint examines the potential role of filtered sunlight phototherapy in addressing the burden of neonatal hyperbilirubinaemia in low- and middle-income countries (LMICs) based on evidence from randomised clinical trials.",
  "authors": [
    {
      "affiliations": [
        "Director, Centre for Healthy Start Initiative, Lagos, Nigeria"
      ],
      "name": "Bolajoko O Olusanya"
    },
    {
      "affiliations": [
        "Massey Street Children’s Hospital, Lagos, Nigeria"
      ],
      "name": "Abieyuwa A Emokpae"
    },
    {
      "affiliations": [
        "Massey Street Children’s Hospital, Lagos, Nigeria"
      ],
      "name": "Cecilia Abimbola Mabogunje"
    }
  ],
  "title": "Filtered-sunlight phototherapy for neonatal jaundice in low-resource settings: evidence for action",
  "uid": "beadaba4-db50-598b-a333-b3df6a6a403d"
}